Potential Sunitinib-Induced Coronary Artery and Aortic Dissections

Area of Science:

• Oncology
• Cardiology
• Pharmacology

Background:

• Small-molecule multitargeted tyrosine kinase inhibitors (TKIs) are a cornerstone of modern cancer therapy.
• Cardiovascular toxicities, such as aortic dissection, are recognized adverse effects of TKI treatment.
• The spectrum of TKI-associated cardiovascular complications requires ongoing investigation.

Observation:

• A patient undergoing treatment with a multitargeted tyrosine kinase inhibitor (TKI) developed a coronary dissection.
• This event represents a novel cardiovascular complication potentially attributable to TKI therapy.

Findings:

• This case study describes the first instance of coronary dissection potentially associated with multitargeted tyrosine kinase inhibitor (TKI) treatment.
• The findings highlight a previously unrecognized cardiovascular risk associated with this class of drugs.

Implications:

• Clinicians should be vigilant for potential cardiovascular adverse events, including coronary dissection, in patients receiving TKI therapy.
• Further research is warranted to elucidate the mechanisms underlying TKI-induced coronary dissection and to inform clinical management strategies.
• This case expands the understanding of the cardiovascular safety profile of tyrosine kinase inhibitors in oncology.